Modern Drug Development Depends on RWD

Drug developers and other life sciences organizations now have access to troves of real-world data (RWD) that can accelerate research and market access efforts. RWD and the real-world evidence generated let researchers study the effects of drugs in real-world conditions and make comparisons that may not be feasible in traditional clinical trial formats.

According to Pat Jenakanandhini, “RWD bridges the gap between research and practice. Drug developers study how a broad group of patients uses and responds to a drug to understand how patient characteristics and behaviors affect health outcomes — data that informs decisions for care. RWD also empowers organizations to design and conduct better studies and clinical trials, which don’t necessarily represent real-world settings. Drug developers share and analyze RWD, applying the results of their analyses to product development and approval. This collaboration between drug developers requires a data fabric architecture to help life sciences firms overcome data silos, friction, and noise to maximize available RWD.”

To read more, click here.

(Source: Med City News, March 13^th, 2023)